Cargando…

Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study

INTRODUCTION: Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism (HPT). This study focused on testing whether a prescription of low-dose cinacalcet on alternate days could be an option for treatment of secondary HPT. MATERIALS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gojaseni, Pongsathorn, Pattarathitinan, Dolnapa, Chittinandana, Anutra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304993/ https://www.ncbi.nlm.nih.gov/pubmed/28223837 http://dx.doi.org/10.2147/IJNRD.S124844

Ejemplares similares

Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients
por: Gojaseni, Pongsathorn, et al.
Publicado: (2010)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
por: Nakayama, Kazunori, et al.
Publicado: (2013)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
por: Conzo, Giovanni, et al.
Publicado: (2012)

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism
por: Susantitaphong, Paweena, et al.
Publicado: (2019)

The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
por: Ngamkam, Jaruwan, et al.
Publicado: (2021)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience
por: Mogl, M. T., et al.
Publicado: (2020)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series
por: Ohri, Alpana, et al.
Publicado: (2022)

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review
por: Li, Xiaosong, et al.
Publicado: (2023)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Successful Early Treatment of Severe Neonatal Hyperparathyroidism With Cinacalcet
por: Thakkar, Keya, et al.
Publicado: (2021)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2018)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dn5gduh2eqrri10ig97grkrrcf